Multitargeted enzyme inhibition in the treatment of cancer. Development of pemetrexed;Multi-targeted-enzyminhibition in der tumortherapie. Entwicklung von pemetrexed

Onkologe

Volumn 11, Issue 12, 2005, Pages 1321-1340

  Hanauske, A R ^a   Peters, H D ^b  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

^b NONE

Author keywords

Chemotherapy; Malignant pleural mesothelioma; Multitargeted antifolate; Non small cell lung cancer; Pemetrexed

Indexed keywords

ANTHRACYCLINE; ANTHRAQUINONE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ENZYME; EPIRUBICIN; FOLIC ACID ANTAGONIST; GEMCITABINE; IRINOTECAN; LOMETREXOL; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; RALTITREXED; VITAMIN;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FOLATE METABOLISM; HUMAN; INFECTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PANCREAS CARCINOMA; PARESTHESIA; PLEURA MESOTHELIOMA; REVIEW; STOMATITIS; THROMBOCYTOPENIA; UTERINE CERVIX CARCINOMA; VITAMIN SUPPLEMENTATION; VOMITING;

EID: 30444457437     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-005-0983-5     Document Type: Review

References (47)

1. Adjei AA, Erlichman C, Sloan JA et al. (2000) Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 18: 1748-1757
2. Atkins JN, Jacobs S, Wieand S et al. (2003) Pemetrexed and oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the NSABP foundation research program. Abstract 1108. Proc Am Soc Clin Oncol 22: 276
3. Awada A, Clark R, Dumez H et al. (2004) Phase I trial of pemetrexed plus paclitaxel administered every 21 days in patients with advanced solid tumors. J Clin Oncol [Suppl 14S] 22: Abstract 2053
4. Celio L, Bajetta E, Toffolatti L et al. (2000) Phase II trial of pemetrexed disodium administered every 21 days in patients with and without folic acid. Abstract 284P. Ann Oncol 11: 65
5. Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP (2002) Phase II trial of pemetrexed disodium (ALIMTA®, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 13: 737-741
6. Cripps C, Burnell M, Jolivet J et al. (1999) Phase II study of first-line LY-231514 (multitargeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC clinical trials group study. Ann Oncol 10: 1175-1179
7. Cunningham D, Zalcberg JR, Rath U et al. (1996) Final results of a randomised trial comparing "tomudex" (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 7: 961-965
8. Dittrich C, Petruzelka L, Vodvarka P et al. (2003) Pemetrexed and cyclophosphamide in patients with locally advanced or metastatic breast cancer: a phase I study. Abstract 159. Proc Am Soc Clin Oncol 22: 40
9. Goedhals L, Wijk AL van (1998) MTA (LY231514) in advanced carcinoma of the cervix. Ann Oncol 9: 339
10. Gralla Rj, Hollen PJ, Liepa M et al. (2003) Improving quality of life in patients with malignant pleural mesothelioma: results of the randomised pemetrexed + cisplatin vs. cisplatin trial using the LCSS-meso instrument. Abstract 2496. Proc Am Soc Clin Oncol 22: 621
11. Hanna N, Shepherd FA, Fossella FV et al. (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597
12. Hochster H (2002) The role of pemetrexed in the treatment of colorectal cancer. Semin Oncol [Suppl 18] 29: 54-56
13. Hughes AN, Lind M, Azzabi A et al. (2001) A phase I dose escalation study of doxorubicin in combination with pemetrexed (ALIMTA, multitargeted antifolate). 24th Annual San Antonio Breast Cancer Symposium, San Antonio, Abstract 438
14. Hughes A, Calvert P, Azzabi A et al. (2002) Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20: 3533-3544
15. John W, Picus J, Blanke CD et al. (2000) Activity fo multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer 88: 1807-1813
16. Kindler HL, Dugan W, Hochster H, Strickland D, Jacobs A, John WJ (2002) Clinical outcome in patients (pts) with advanced pancreatic cancer treated with pemetrexed/gemcitabine. Proc Am Soc Clin Oncol 21: Abstract 499
17. Kroening H, Hochster H, Grothey A et al. (2003) Pemetrexed and irinotecan as second-line therapy for locally advanced or metastatic colorectal cancer: a phase I dose escalation study. Abstract 1459. Proc Am Soc Clin Oncol 22: 363a
18. Llombart-Cussac A, Theodoulou M, Rowland K, Lassus M, Cruciani S (2000) A phase II trial of pemetrexed disodium (ALIMTA™, LY231514, MTA) in metastatic breast cancer (MBC) patients who have failed anthracyclines (A) and taxanes (T) (salvage chemotherapy). Abstract 526. Breast Cancer Res Treat 64: 122
19. Mackay H, Carmichael J, Roberts J et al. (2002) Phase I study of pemetrexed in combination with docetaxel in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 21: Abstract 2120
20. Manegold C, Gatzemeier U, Pawel J von, Pirker R, Malayeri R, Krejcy K (2000) Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol 11: 435-440
21. Martin M, Spielmann M, Namer M et al. (2003) Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann Oncol 14: 1246-1252
22. Mennel RG, O'Shaughnessy J, Blum JL, Snyder D, Lassus M (2001) Pemetrexed disodium (ALIMTA™, LY231514, MTA) in advanced breast cancer (ABC) patients (pts) with prior anthracycline or anthracenedione, taxane and capecitabine treatment: a phase II study. Abstract 194. Proc Am Soc Oncol 20: 49a
23. Miles DW, Smith IE, Coleman RE, Calvert AH, Lind MJ (2001) A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur J Cancer 37: 1366-1371
24. Miller KD, Picus J, Blanke C et al. (2000) Phase II study of the multitargeted antifolate LY-231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 11: 101-113
25. Millward M, Clarke S, Beale P et al. (2001) Phase I trial of pemetrexed (Alimta) and vinorelbine in patients (pts) with advanced cancer. Abstract 2102. Proc Am Soc Clin Oncol 20: 88b
26. Misset JL, Gamelin E, Campone M et al. (2004) Phase I and pharmocokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Ann Oncol 15: 1123-1129
27. Oettle H, Richards D, Ramanathan RK et al. (2005) A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16: 1639-1645
28. Paridaens R, Dirix L, Mellaerts N et al. (2002) Phase I study of pemetrexed (ALIMTA) and epirubicin in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 76: Abstract 290
29. Paz-Ares L, Tabernero J, Moyano A et al. (1998) Significant activity of the multitargeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder: results of a phase II trial. Ann Oncol 9: 292
30. Pivot X, Raymond E, Laguerre B et al. (2001) Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 85: 649-655
31. Richards DA, Kindler HL, Oettle H et al. (2004) A randomised phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. J Clin Oncol [Suppl 14S] 22: Abstract 4007
32. Rinaldi DA, Kuhn JG, Burris HA et al. (1999) A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44: 372-380
33. Rusthoven JJ, Eisenhauer E, Butts C et al. (1999) Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small cell lung cancer: a phase II study. J Clin Oncol 17: 1194-1199
34. 12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21: 1556-1561
35. Shepherd FA, Arnold A, Neville A et al. (2000) Phase II study of MTA (Alimta) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC). Abstract 1984. Proc Am Soc Clin Oncol 19: 507a
36. Shih C, Thornton DE (1999) Preclinical pharmacology studies and the clinical development of a novel multitargeted antifolate, MTA (LY231514). In: Jackman AL (ed) Antifolate drugs in cancer therapy. Humana Press, Totowa, NJ, pp 183-201
37. Shih C, Chen VJ, Gossett LS et al. (1997) LY231514, a pyrrol[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57: 1116-2011
38. Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schlutz RM (1998) Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 38: 135-152
39. Smit EF, Mattson K, Pawel J von, Manegold C, Clarke S, Postums PE (2003) ALIMTA® (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 14: 455-460
40. Sweeney C, Baker S, Murry D et al. (2001) Pharmacokinetic (PK) and pharmacodynamic analysis of aspirin administered with multi-targeted antifolate (ALIMTA). Abstract 104. Eur J Cancer [Suppl 6] 37: 31
41. Takimoto CH, Forero L, Baker SD et al. (2002) Phase I and pharmocokinetic study of LY231514 (pemetrexed disodium, MTA) in renal dysfunction patients. Abstract 41PD. Ann Oncol [Suppl 5] 13: 12
42. Taylor EC, Patel HH (1992) Synthesis of pyrazolo(3,4,-d)pyrimidine analogues of the potent antitumor agent n-{4-(2-(2-amino-4(3 h)-oxo-7h-pyrro-lo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl}-1-glutamic acid (LY2231514). Tetrahedron Lett 48: 8089-8100
43. Thödtmann R, Depenbrock H, Dumez H et al. (1999) Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 17: 3009-3016
44. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644
45. Vokes E, Szeto L, Mauer A et al. (2003) A phase I trial of pemetrexed + chest radiotherapy in patients with advanced or metastatic non-small-cell lung cancer or esophageal cancer. 10th World Congress of Lung Cancer, Vancouver, Canada, Abstract D-308
46. Westerhof GR, Schornagel JH, Kathmann I et al. (1985) Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 48: 459-471
47. Woodland JM, Barnett CJ, Dorman DE et al. (1997) Metabolism and disposition of antifolate LY231514 in mice and dogs. Drug Metab Dispos 25: 693-700